18780970|t|Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.
18780970|a|The objective of this study was to determine if the phosphodiesterase 5 (PDE-5) inhibitor, sildenafil, could be used as a neuroprotective agent in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) murine model of Parkinson's disease. The underlying hypothesis of these studies is that blockade of PDE-5 catabolism of cGMP will attenuate the loss of nigrostriatal dopamine (NSDA) neurons following chronic neurotoxin exposure. Chronic MPTP-treated mice were administered sildenafil using three different regimens. Animals were: 1) treated with sildenafil and then exposed to chronic MPTP; 2) treated concurrently with sildenafil and MPTP; and 3) first exposed to MPTP and subsequently treated with sildenafil. End points of neurotoxicity included dopamine (DA) and tyrosine hydroxylase (TH) concentrations in NSDA axon terminals in the striatum, and stereological cell counts of TH immunoreactive neurons in the substantia nigra. Results reveal that sildenafil did not prevent neurotoxicity produced by chronic MPTP exposure regardless of the treatment paradigms employed. On the other hand, sildenafil did not produce any deleterious effect on NSDA neuron function nor did it potentiate the neurotoxic effects of MPTP. These results suggest that sildenafil would not accelerate DA cell loss when used as a treatment for erectile dysfunction in men diagnosed with Parkinson's disease.
18780970	11	21	sildenafil	Chemical	MESH:D000068677
18780970	39	47	dopamine	Chemical	MESH:D004298
18780970	61	67	murine	Species	10090
18780970	77	96	Parkinson's disease	Disease	MESH:D010300
18780970	150	169	phosphodiesterase 5	Gene	242202
18780970	171	176	PDE-5	Gene	242202
18780970	189	199	sildenafil	Chemical	MESH:D000068677
18780970	255	299	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
18780970	301	305	MPTP	Chemical	MESH:D015632
18780970	307	313	murine	Species	10090
18780970	323	342	Parkinson's disease	Disease	MESH:D010300
18780970	407	412	PDE-5	Gene	242202
18780970	427	431	cGMP	Chemical	MESH:D006152
18780970	473	481	dopamine	Chemical	MESH:D004298
18780970	483	487	NSDA	CellLine	CVCL:KS83
18780970	544	548	MPTP	Chemical	MESH:D015632
18780970	557	561	mice	Species	10090
18780970	580	590	sildenafil	Chemical	MESH:D000068677
18780970	653	663	sildenafil	Chemical	MESH:D000068677
18780970	692	696	MPTP	Chemical	MESH:D015632
18780970	727	737	sildenafil	Chemical	MESH:D000068677
18780970	742	746	MPTP	Chemical	MESH:D015632
18780970	772	776	MPTP	Chemical	MESH:D015632
18780970	807	817	sildenafil	Chemical	MESH:D000068677
18780970	833	846	neurotoxicity	Disease	MESH:D020258
18780970	856	864	dopamine	Chemical	MESH:D004298
18780970	866	868	DA	Chemical	MESH:D004298
18780970	874	894	tyrosine hydroxylase	Gene	21823
18780970	896	898	TH	Gene	21823
18780970	918	922	NSDA	CellLine	CVCL:KS83
18780970	988	990	TH	Gene	21823
18780970	1059	1069	sildenafil	Chemical	MESH:D000068677
18780970	1086	1099	neurotoxicity	Disease	MESH:D020258
18780970	1120	1124	MPTP	Chemical	MESH:D015632
18780970	1201	1211	sildenafil	Chemical	MESH:D000068677
18780970	1254	1258	NSDA	CellLine	CVCL:KS83
18780970	1301	1311	neurotoxic	Disease	MESH:D020258
18780970	1323	1327	MPTP	Chemical	MESH:D015632
18780970	1356	1366	sildenafil	Chemical	MESH:D000068677
18780970	1388	1390	DA	Chemical	MESH:D004298
18780970	1430	1450	erectile dysfunction	Disease	MESH:D007172
18780970	1454	1457	men	Species	9606
18780970	1473	1492	Parkinson's disease	Disease	MESH:D010300
18780970	Negative_Correlation	MESH:D015632	MESH:D010300
18780970	Association	MESH:D004298	MESH:D007172
18780970	Positive_Correlation	MESH:D015632	MESH:D020258
18780970	Negative_Correlation	MESH:D000068677	MESH:D007172
18780970	Negative_Correlation	MESH:D000068677	242202
18780970	Association	MESH:D004298	MESH:D020258
18780970	Association	MESH:D006152	242202
18780970	Association	MESH:D004298	MESH:D010300
18780970	Negative_Correlation	MESH:D000068677	MESH:D010300

